Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HbA1c Variability and Treatment Thresholds in Type 2 Diabetes
NCT02879409Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2016
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Standard deviation of HbA1c. Started Nov 2016; status: active, not recruiting.
Beyond the preview
Go deeper on NCT02879409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879409.